Pfizer ends PDC deal with CytomX

CytomX Therapeutics Inc. (NASDAQ:CTMX) disclosed in its 4Q17 earnings that it received notification that Pfizer Inc. (NYSE:PFE) plans to terminate a 2013

Read the full 226 word article

User Sign In